Alberto Lleó Bisa

Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Author Correction: GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Rongve, A, Witoelar, A, Ruiz, A et al. Sci Rep 2019
    PMID:31619746

  2. Optimal management of oil content variability in olive mill batches by NIR spectroscopy. Correa, EC, Roger, JM, Lleó, L et al. Sci Rep 2019
    PMID:31562395

  3. Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity. Mollica, MA, Tort-Merino, A, Navarra, J et al. Cortex 2019
    PMID:31561128

  4. The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. Lleo, A, Leung, PSC, Hirschfield, GM et al. Semin. Liver Dis. 2019
    PMID:31537031

  5. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Shi, L, Westwood, S, Baird, AL et al. Alzheimers Dement 2019
    PMID:31495601

  6. Toothbrushes may convey bacteria to the cystic fibrosis lower airways. Passarelli Mantovani, R, Sandri, A, Boaretti, M et al. J Oral Microbiol 2019
    PMID:31489126

  7. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Moreno-Grau, S, de Rojas, I, Hernández, I et al. Alzheimers Dement 2019
    PMID:31473137

  8. Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Alcolea, D, Pegueroles, J, Muñoz, L et al. Ann Clin Transl Neurol 2019
    PMID:31464088

  9. Safety of vedolizumab in liver transplant recipients: A systematic review. Spadaccini, M, Aghemo, A, Caprioli, F et al. United European Gastroenterol J 2019
    PMID:31428411

  10. Author Correction: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Kunkle, BW, Grenier-Boley, B, Sims, R et al. Nat. Genet. 2019
    PMID:31417202

  11. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Deming, Y, Filipello, F, Cignarella, F et al. Sci Transl Med 2019
    PMID:31413141

  12. Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. Bonham, LW, Steele, NZR, Karch, CM et al. Sci Rep 2019
    PMID:31350420

  13. All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis. Roda, G, Lleo, A, Danese, S et al. Clin. Gastroenterol. Hepatol. 2019
    PMID:31323379

  14. The risk of liver cancer in autoimmune liver diseases. Lleo, A, de Boer, YS, Liberal, R et al. Ther Adv Med Oncol 2019
    PMID:31320937

  15. Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. Esteve, P, Rueda-Carrasco, J, Inés Mateo, M et al. Nat. Neurosci. 2019
    PMID:31308530

Search PubMed